Genitourinary Cancer

Top Story

Morbidity burden identifies testicular cancer survivors who need close monitoring

May 22, 2018
Meeting News

Rheumatic adverse effects of immune checkpoint therapy 'poorly recognized' in studies

May 22, 2018
DESTIN, Fla. — Although the incidence of rheumatologic adverse effects associated with immune checkpoint inhibitors is expected to grow with their increased use…
In the Journals Plus

US cancer deaths continue to decline

May 22, 2018
Cancer deaths continue to decline among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer. Deaths due to…
FDA News

FDA issues alert on decreased survival with pembrolizumab or atezolizumab for urothelial cancer

May 21, 2018
The FDA alerted health care professionals and clinical investigators to decreased survival associated with pembrolizumab or atezolizumab monotherapy for the treatment of…
More Headlines »
CME

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

The integration of immune checkpoint inhibitors into treatment algorithms for patients with bladder cancer who have…
More »
Video
Meeting News

VIDEO: Stereotactic radiotherapy preferred for brain metastases from renal cell carcinoma

November 5, 2017
More »
Resource Centers
Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

CME CNE CPE

Immune Checkpoint Inhibitors for Genitourinary Cancers: Practice Essential for Community Oncologists and Advanced Practice Providers

This activity is supported by an educational grant from Merck & Co., Inc.

For many years, the mainstay of initial treatment for metastatic bladder cancer has been chemotherapy. However…
More »